Virotherapy of Canine Tumors with Oncolytic Vaccinia Virus GLV-1h109 Expressing an Anti-VEGF Single-Chain Antibody

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Patil, Sandeep S ^a   Gentschev, Ivaylo ^a,b   Adelfinger, Marion ^a   Donat, Ulrike ^a   Hess, Michael ^a   Weibel, Stephanie ^a   Nolte, Ingo ^c   Frentzen, Alexa ^b   Szalay, Aladar A ^a,b,d,e  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b GENELUX CORPORATION   (United States)

^c UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

^d UNIVERSITY OF WÜRZBURG   (Germany)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; PROTEIN GLAF 1; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VIRUS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ARTICLE; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; DOG DISEASE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FEMALE; IMMUNOMODULATION; MOUSE; NONHUMAN; ONCOLYTIC VACCINIA VIRUS GLV 1H109; ONCOLYTIC VIROTHERAPY; PROSTATE CARCINOMA; PROTEIN EXPRESSION; SARCOMA CELL; SOFT TISSUE SARCOMA; SOLID TUMOR; TUMOR CELL DESTRUCTION; TUMOR XENOGRAFT; VACCINIA; VACCINIA VIRUS; VIRAL GENE DELIVERY SYSTEM; VIRUS REPLICATION; VIRUS STRAIN;

ANIMALS; CELL LINE; CELL SURVIVAL; DOG DISEASES; DOGS; FEMALE; GENE EXPRESSION; GENE ORDER; GENETIC VECTORS; GLUCURONIDASE; HUMANS; MICE; MICE, NUDE; NEOPLASMS; ONCOLYTIC VIROTHERAPY; SINGLE-CHAIN ANTIBODIES; TUMOR BURDEN; VACCINIA VIRUS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84867606567     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0047472     Document Type: Article

References (39)

1. Merlo DF, Rossi L, Pellegrino C, Ceppi M, Cardellino U, et al. (2008) Cancer incidence in pet dogs: findings of the Animal Tumor Registry of Genoa, Italy. J Vet Intern Med 22: 976-984.
2. Kelsey JL, Moore AS, Glickman LT, (1998) Epidemiologic studies of risk factors for cancer in pet dogs. Epidemiol Rev 20: 204-217.
3. Patil SS, Gentschev I, Nolte I, Ogilvie G, Szalay AA, (2012) Oncolytic virotherapy in veterinary medicine: current status and future prospects for canine patients. J Transl Med 10: 3.
4. Gentschev I, Adelfinger M, Josupeit R, Rudolph S, Ehrig K, et al. (2012) Preclinical evaluation of oncolytic vaccinia virus for therapy of canine soft tissue sarcoma. PLoS One 7: e37239.
5. Reimann-Berg N, Willenbrock S, Murua Escobar H, Eberle N, Gerhauser I, et al. (2011) Two new cases of polysomy 13 in canine prostate cancer. Cytogenet Genome Res 132: 16-21.
6. Zhang Q, Yu YA, Wang E, Chen N, Danner RL, et al. (2007) Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus. Cancer Res 67: 10038-10046.
7. Frentzen A, Yu YA, Chen N, Zhang Q, Weibel S, et al. (2009) Anti-VEGF single-chain antibody GLAF-1 encoded by oncolytic vaccinia virus significantly enhances antitumor therapy. Proc Natl Acad Sci U S A 106: 12915-12920.
8. Falkner FG, Moss B, (1990) Transient dominant selection of recombinant vaccinia viruses. J Virol 64: 3108-3111.
9. Liang WC, Wu X, Peale FV, Lee CV, Meng YG, et al. (2006) Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. J Biol Chem 281: 951-961.
10. Ferrara N, Gerber HP, LeCouter J, (2003) The biology of VEGF and its receptors. Nat Med 9: 669-676.
11. Folkman J, (2007) Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 6: 273-286.
12. Kamstock D, Elmslie R, Thamm D, Dow S, (2007) Evaluation of a xenogeneic VEGF vaccine in dogs with soft tissue sarcoma. Cancer Immunol Immunother 56: 1299-1309.
13. Quesada AR, Medina MA, Alba E, (2007) Playing only one instrument may be not enough: limitations and future of the antiangiogenic treatment of cancer. Bioessays 29: 1159-1168.
14. Gerber HP, Ferrara N, (2005) Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 65: 671-680.
15. Hess M, Stritzker J, Hartl B, Sturm JB, Gentschev I, et al. (2011) Bacterial glucuronidase as general marker for oncolytic virotherapy or other biological therapies. J Transl Med 9: 172.
16. Weibel S, Stritzker J, Eck M, Goebel W, Szalay AA, (2008) Colonization of experimental murine breast tumours by Escherichia coli K-12 significantly alters the tumour microenvironment. Cell Microbiol 10: 1235-1248.
17. Gentschev I, Muller M, Adelfinger M, Weibel S, Grummt F, et al. (2011) Efficient colonization and therapy of human hepatocellular carcinoma (HCC) using the oncolytic vaccinia virus strain GLV-1h68. PLoS One 6: e22069.
18. Peranzoni E, Zilio S, Marigo I, Dolcetti L, Zanovello P, et al. (2010) Myeloid-derived suppressor cell heterogeneity and subset definition. Curr Opin Immunol 22: 238-244.
19. de Queiroz GF, Dagli ML, Fukumasu H, Zavala AA, Matera JM, (2010) Vascular endothelial growth factor expression and microvascular density in soft tissue sarcomas in dogs. J Vet Diagn Invest 22: 105-108.
20. Zizzo N, Patruno R, Zito FA, Di Summa A, Tinelli A, et al. (2010) Vascular endothelial growth factor concentrations from platelets correlate with tumor angiogenesis and grading in a spontaneous canine non-Hodgkin lymphoma model. Leuk Lymphoma 51: 291-296.
21. Patruno R, Arpaia N, Gadaleta CD, Passantino L, Zizzo N, et al. (2009) VEGF concentration from plasma-activated platelets rich correlates with microvascular density and grading in canine mast cell tumour spontaneous model. J Cell Mol Med 13: 555-561.
22. Hemminki A, Kanerva A, Kremer EJ, Bauerschmitz GJ, Smith BF, et al. (2003) A canine conditionally replicating adenovirus for evaluating oncolytic virotherapy in a syngeneic animal model. Mol Ther 7: 163-173.
23. Suter SE, Chein MB, von Messling V, Yip B, Cattaneo R, et al. (2005) In vitro canine distemper virus infection of canine lymphoid cells: a prelude to oncolytic therapy for lymphoma. Clin Cancer Res 11: 1579-1587.
24. Gentschev I, Stritzker J, Hofmann E, Weibel S, Yu YA, et al. (2009) Use of an oncolytic vaccinia virus for the treatment of canine breast cancer in nude mice: preclinical development of a therapeutic agent. Cancer Gene Ther 16: 320-328.
25. Gentschev I, Ehrig K, Donat U, Hess M, Rudolph S, et al. (2010) Significant Growth Inhibition of Canine Mammary Carcinoma Xenografts following Treatment with Oncolytic Vaccinia Virus GLV-1h68. J Oncol 2010: 736907.
26. Arendt M, Nasir L, Morgan IM, (2009) Oncolytic gene therapy for canine cancers: teaching old dog viruses new tricks. Vet Comp Oncol 7: 153-161.
27. Padera TP, Stoll BR, Tooredman JB, Capen D, di Tomaso E, et al. (2004) Pathology: cancer cells compress intratumour vessels. Nature 427: 695.
28. Jain RK, (2001) Delivery of molecular and cellular medicine to solid tumors. Adv Drug Deliv Rev 46: 149-168.
29. Gerber HP, Kowalski J, Sherman D, Eberhard DA, Ferrara N, (2000) Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor. Cancer Res 60: 6253-6258.
30. Winkler F, Kozin SV, Tong RT, Chae SS, Booth MF, et al. (2004) Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6: 553-563.
31. Gregory AD, Houghton AM, (2011) Tumor-associated neutrophils: new targets for cancer therapy. Cancer Res 71: 2411-2416.
32. Nathan C, (2006) Neutrophils and immunity: challenges and opportunities. Nat Rev Immunol 6: 173-182.
33. Ruffell B, Affara NI, Coussens LM, (2012) Differential macrophage programming in the tumor microenvironment. Trends Immunol 33: 119-126.
34. Ochando JC, Chen SH (2012) Myeloid-derived suppressor cells in transplantation and cancer. Immunol Res.
35. Gil M, Bieniasz M, Seshadri M, Fisher D, Ciesielski MJ, et al. (2011) Photodynamic therapy augments the efficacy of oncolytic vaccinia virus against primary and metastatic tumours in mice. Br J Cancer 105: 1512-1521.
36. Breitbach CJ, Paterson JM, Lemay CG, Falls TJ, McGuire A, et al. (2007) Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow. Mol Ther 15: 1686-1693.
37. John LB, Howland LJ, Flynn JK, West AC, Devaud C, et al. (2012) Oncolytic virus and anti-4-1BB combination therapy elicits strong antitumor immunity against established cancer. Cancer Res 72: 1651-1660.
38. Fridlender ZG, Sun J, Kim S, Kapoor V, Cheng G, et al. (2009) Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN. Cancer Cell 16: 183-194.
39. Gentschev I, Donat U, Hofmann E, Weibel S, Adelfinger M, et al. (2010) Regression of human prostate tumors and metastases in nude mice following treatment with the recombinant oncolytic vaccinia virus GLV-1h68. J Biomed Biotechnol 2010: 489759.